Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Deals & M&A

Viatris takes control of Pacira, guiding to $90–100m of sales by year-end

The generics and brands group has taken full ownership of the pain-focused drugmaker, and says the business should add up to $100 million in revenue before the calendar year closes.

17 Nov 2026 · Viatris Inc VTRS · Company news

Viatris has taken full ownership of Pacira BioSciences, a US company that focuses on pain treatments that do not rely on opioids. The group announced on 17 November 2026 that the transaction is done, and that it expects the newly acquired business to bring in $90–100 million of revenue between that date and 31 December.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Viatris Inc ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Deals & M&AAll →